This program is part of a series of Topics in Neurology programs; Click Here for information.
An advancing knowledge of the neuropathological processes leading to Alzheimer's disease (AD) is causing major shifts in how the condition is diagnosed and managed. Recent changes – including the development of new diagnostic categories aimed at an earlier diagnosis, the incorporation of biomarkers into clinical practice, and the approval of an amyloid imaging agent – are making AD management increasingly complex.
The push for earlier diagnosis presents many treatment challenges for practicing clinicians, as little is known about the efficacy of existing agents in these earlier clinical phases of disease. In addition, emerging agents are interfering with the deposition of proteins thought responsible for neuronal damage, as opposed to current agents which attempt to compensate for already damaged neurons. This program will address these changes in the diagnosis and treatment of AD, to ensure that clinicians continue to improve the care of their AD patients.
This activity is intended for neurologists, psychiatrists, geriatricians, primary care providers, and other clinicians involved in the care of older adults.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Describe the new diagnostic categories of AD and the impact that these new categories have on diagnosis and treatment considerations
- Develop plans to incorporate newer diagnostic tools and biomarker assessments into the earlier diagnosis and treatment of individuals with AD
- Devise appropriate, evidence-based treatment plans for individuals across each diagnostic category of AD
Speaking Faculty / Steering Committee
Marwan Sabbagh, MD, FAAN
Banner Sun Health Research Institute
Research Professor of Neurology
University of Arizona College of Medicine-Phoenix
Sun City, AZ
Marwan Sabbagh, MD, FAAN is a board-certified neurologist and geriatric neurologist, and hopes to work himself out of a job. Considered one of the leading experts in Alzheimer's and dementia, he is the Director of Banner Sun Health Research Institute (BSHRI), and has dedicated his entire career to finding a cure for Alzheimer's and other age-related neurodegenerative diseases.
Dr. Sabbagh is a leading investigator for many prominent national Alzheimer's prevention and treatment trials, including Alzheimer immunotherapy studies. He is Senior Editor for
the Journal of Alzheimer's Disease and for Clinical Neurology News. He has authored or coauthored almost 200 medical and scientific articles on Alzheimer's research. Dr. Sabbagh authored The Alzheimer's Answer, with a forward written by Justice Sandra Day O'Connor, and edited Palliative Care for Advanced Alzheimer's and Dementia: Guidelines and Standards
for Evidence Based Care. His new book, The Alzheimer's Prevention Cookbook: 100 Recipes to Better Brain Health, is due to be released shortly. He also edited the Handbook of Geriatric Neurology, which is now in press.
Dr. Sabbagh is also the Director of Clinical Research at BSHRI and Senior Scientist for the Haldeman Laboratory for Molecular Diagnostics and Therapeutics. In addition to his
clinical work and private practice in Sun City, Dr. Sabbagh is Associate Director of the Arizona Alzheimer's Disease Core Center, a clinical instructor in the Banner/St. Joseph's Geriatric Fellowship Program, and a Research Professor of Neurology at the University of Arizona College of Medicine-Phoenix.
Dr. Sabbagh earned his undergraduate degree from the University of California Berkeley and his medical degree from the University of Arizona in Tucson. He received his residency training in neurology at Baylor College of Medicine and completed his fellowship in geriatric neurology and dementia at the UCSD School of Medicine.
Sanjay Asthana, MD, FACP, FRCP(C)
Professor of Medicine
Duncan G. Ballantine Chair in Geriatrics
Chief, Division of Geriatrics
Director, NIA/NIH Wisconsin Alzheimer's Disease Research Center
Director, Madison VA GRECC
University of Wisconsin School of Medicine and Public Health
Sanjay Asthana, MD, FACP, FRCP(C) is a Professor of Medicine and the Duncan G. Ballantine Chair in Geriatrics at the University of Wisconsin School of Medicine and Public Health in Madison, WI. He also serves as the Director of both the NIA/NIH Wisconsin Alzheimer's Disease Research Center and the Madison VA GRECC. After earning his
medical doctorate from the University of Delhi in New Delhi, India, Dr. Asthana completed a residency, eventually serving as Chief Resident, at the University of Saskatchewan
School of Medicine; a research fellowship in geriatric medicine at the Johns Hopkins University School of Medicine; and a senior staff fellowship in neurosciences at the National Institute on Aging.
Dr. Asthana has extensive administrative and research experience in developing, overseeing, and managing large research programs and multisite intervention studies involving subjects with Alzheimer's disease (AD) and mild cognitive impairment (MCI), as well as healthy older controls. Funded continuously by the NIH for more than 18 years, he has published extensively in the fields of hormone therapy, AD, and gerontology and has trained more than 40 physician-scientists and PhD investigators in dementia and aging research.
The author or co-author of numerous peer-reviewed articles on AD, Dr. Asthana also serves as Associate Editor of Hazzard's Principles of Geriatrics and Gerontology; Co-chair of the Dementia Steering Committee at the Department of Veterans Affairs in Washington, DC; and Director of the Hartford Center of Excellence in Geriatric Medicine and Education at the University of Wisconsin.
R. Scott Turner, MD, PhD
Professor of Neurology
Director, Memory Disorders Program
Georgetown University Medical Center
R. Scott Turner, MD, PhD is a Professor of Neurology and Director of the Memory Disorders Program at Georgetown University Medical Center in Washington, DC. Dr.Turner and his team are dedicated to providing state-of-the-art clinical services for individuals affected by Alzheimer's disease (AD) and related disorders and to conducting research aimed at improving treatment options for AD. He previously served as Chief of the Neurology Service at the VA Medical Center and Associate Professor of Neurology at the University of Michigan in Ann Arbor.
Dr. Turner was awarded both MD and PhD degrees from Emory University in Atlanta. He then completed an internship in internal medicine and a residency and fellowship in neurology at the University of Pennsylvania Health System in Philadelphia. Dr. Turner has authored or co-authored more than 70 peer-reviewed publications, as well as several editorials, reviews, and book chapters. Among numerous research awards, Dr. Turner was a Howard Hughes Medical Scholar and a Beeson Scholar. He is an elected Fellow of the American Neurological Association and a recipient of a 2012 Washington Monument Award from the National Capital Area Chapter of the Alzheimer's Association.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, the post-test, or evaluation, please email firstname.lastname@example.org.
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program sponsored by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
Method of Participation
To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be provided upon submission of a completed evaluation form.
There is no fee associated with this program.
Event staff will be glad to assist you with any special needs. Please email email@example.com at least 5 days prior to the program.
Jointly Sponsored By
Jointly sponsored by Potomac Center for Medical Education and Rockpointe
This program is supported through an educational grant from Lilly USA, LLC and Novartis Pharmaceutical Corporation.
By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements above.
Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.